Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

不利影响 临床试验 养生 打开标签 人类免疫缺陷病毒(HIV) 临床终点
作者
David A. Margolis,Juan González-García,Hans Jürgen Stellbrink,Joseph J. Eron,Yazdan Yazdanpanah,Daniel Podzamczer,Thomas A. Lutz,Jonathan B. Angel,Gary Richmond,Bonaventura Clotet,Félix Gutiérrez,Louis Sloan,Marty St. Clair,Miranda Murray,Susan L. Ford,Joseph M. Mrus,Parul Patel,Herta Crauwels,Sandy Griffith,Kenneth Sutton,David Dorey,Kimberly Y. Smith,Peter Williams,William Spreen
出处
期刊:The Lancet [Elsevier BV]
卷期号:390 (10101): 1499-1510 被引量:288
标识
DOI:10.1016/s0140-6736(17)31917-7
摘要

Summary Background Cabotegravir and rilpivirine are antiretroviral drugs in development as long-acting injectable formulations. The LATTE-2 study evaluated long-acting cabotegravir plus rilpivirine for maintenance of HIV-1 viral suppression through 96 weeks. Methods In this randomised, phase 2b, open-label study, treatment-naive adults infected with HIV-1 initially received oral cabotegravir 30 mg plus abacavir–lamivudine 600–300 mg once daily. The objective of this study was to select an intramuscular dosing regimen based on a comparison of the antiviral activity, tolerability, and safety of the two intramuscular dosing regimens relative to oral cabotegravir plus abacavir–lamivudine. After a 20-week induction period on oral cabotegravir plus abacavir–lamivudine, patients with viral suppression (plasma HIV-1 RNA 90%). Difference in proportions and associated 95% CIs were supportive to the primary analysis. The trial is registered at ClinicalTrials.gov, number NCT02120352. Findings Among 309 enrolled patients, 286 were randomly assigned to the maintenance period (115 to each of the 4-week and 8-week groups and 56 to the oral treatment group). This study is currently ongoing. At 32 weeks following randomisation, both long-acting regimens met primary criteria for comparability in viral suppression relative to the oral comparator group. Viral suppression was maintained at 32 weeks in 51 (91%) of 56 patients in the oral treatment group, 108 (94%) of 115 patients in the 4-week group (difference 2·8% [95% CI −5·8 to 11·5] vs oral treatment), and 109 (95%) of 115 patients in the 8-week group (difference 3·7% [−4·8 to 12·2] vs oral treatment). At week 96, viral suppression was maintained in 47 (84%) of 56 patients receiving oral treatment, 100 (87%) of 115 patients in the 4-week group, and 108 (94%) of 115 patients in the 8-week group. Three patients (1%) experienced protocol-defined virological failure (two in the 8-week group; one in the oral treatment group). Injection-site reactions were mild (3648 [84%] of 4360 injections) or moderate (673 [15%] of 4360 injections) in intensity and rarely resulted in discontinuation (two [ Interpretation The two-drug combination of all-injectable, long-acting cabotegravir plus rilpivirine every 4 weeks or every 8 weeks was as effective as daily three-drug oral therapy at maintaining HIV-1 viral suppression through 96 weeks and was well accepted and tolerated. Funding ViiV Healthcare and Janssen R&D.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
zzh_zxc完成签到,获得积分10
3秒前
4秒前
李爱国的应助被richardhipower采纳,获得10
6秒前
7秒前
Hello的应助被TT采纳,获得10
9秒前
望禾完成签到,获得积分10
9秒前
XX完成签到,获得积分10
12秒前
13秒前
handsomeboy完成签到,获得积分10
14秒前
16秒前
137292967发布了新的文献求助10
17秒前
张磊发布了新的文献求助10
17秒前
17秒前
FashionBoy的应助被richardhipower采纳,获得10
17秒前
田様的应助被Cylara采纳,获得10
19秒前
可爱的函函的应助被yuyuyu采纳,获得10
19秒前
20秒前
无助的考拉完成签到,获得积分10
20秒前
20秒前
20秒前
张张发布了新的文献求助10
21秒前
22秒前
K9999K发布了新的文献求助10
22秒前
Lydia发布了新的文献求助10
22秒前
在水一方的应助被zww采纳,获得10
23秒前
华仔的应助被科研通管家采纳,获得10
23秒前
科目三的应助被科研通管家采纳,获得10
23秒前
烟花的应助被科研通管家采纳,获得10
24秒前
秋风的应助被科研通管家采纳,获得10
24秒前
打打的应助被科研通管家采纳,获得30
24秒前
科研通AI2S的应助被科研通管家采纳,获得10
24秒前
隐形曼青的应助被科研通管家采纳,获得10
24秒前
852的应助被科研通管家采纳,获得10
24秒前
领导范儿的应助被科研通管家采纳,获得10
24秒前
生煎包完成签到,获得积分10
24秒前
完美世界的应助被科研通管家采纳,获得10
24秒前
CAOHOU的应助被科研通管家采纳,获得10
25秒前
今后的应助被科研通管家采纳,获得10
25秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192604
求助须知:如何正确求助?哪些是违规求助? 9579105
关于积分的说明 21863529
捐赠科研通 7792211
什么是DOI,文献DOI怎么找? 3436974
关于科研通互助平台的介绍 2560633
邀请新用户注册赠送积分活动 2483864